- €1.29bn
- €1.24bn
- €493.65m
- 95
- 53
- 94
- 97
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 13.55 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | -9.28% | ||
| Dividend Yield (f) | 3.71% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.78 | ||
| Price to Tang. Book | 2.39 | ||
| Price to Free Cashflow | 17.04 | ||
| Price to Sales | 2.62 | ||
| EV to EBITDA | 9.75 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 14.28% | ||
| Return on Equity | 16.04% | ||
| Operating Margin | 21.69% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 380.24 | 398.56 | 438.75 | 451.17 | 493.65 | 531.09 | 568.72 | 6.67% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +14.72 | +6.46 | +9.12 | +4.15 | +21.49 | -18.76 | +15.75 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Faes Farma SA is a Spain-based company engaged in the pharmaceutical industry. The Company specializes in the research, production, distribution and sale of prescription and generic drugs, over-the-counter (OTC) medicines, food supplements and personal care treatments, as well as raw materials for the pharmaceutical use. The Company’s research lines are mainly focused on the development of new drugs for the treatment of allergy, venous insufficiency and irritable bowel syndrome, among others. In addition, it provides animal nutrition products. The Company operates in Spain, Portugal, Chile and Mexico, among others. It controls a number of subsidiaries, such as Laboratorios Vitoria SA, Laboratorios Veris SA, Lazlo International SA, Ingaso Farm SLU, Esfion SA and Biotecnet I MAS D SA.
Directors
- Mariano Ucar Angulo CHM
- Valentin Ruiz Unamunzaga CFO
- Helder Cassis GED
- Gonzalo Lopez Casanueva GED
- Luis Proenca GED
- Francisco Quintanilla Guerra GED
- German Fernandez-Cano Diaz DGD
- Francisco Perello Font DMK
- Carlos Gutierrez Aguero DHR
- Xavier Arnaud OTH
- Jose Luis Diaz Capote OTH
- Irene Diez Merchan OTH
- Isabel Eguidazu Urruticoechea OTH
- Alberto Fernandez Fernandez OTH
- Ana Goicoechea Garcia OTH
- Isidro Hermo Blanco OTH
- Gonzalo Hernandez Herrero OTH
- Mariana Soroa Zubiria OTH
- Gonzalo Fernandez de Valderrama Iribarnegaray SEC
- Carlos de Alcocer Torra LED
- Carmen Basagoiti Pastor DRC
- Francisco Javier Usaola Garcia DRC
- Inigo Zavala Ortiz de la Torre DRC
- Belen Amatriain Corbi IND (59)
- Maria Eugenia Zugaza Salazar IND
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 1st, 1970
- Public Since
- March 25th, 1994
- No. of Employees
- 1,775
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Madrid Stock Exchange- Shares in Issue
- 311,248,691
- Address
- Avda. Autonomia 10, LEIOA, 48940
- Web
- https://faesfarma.com/
- Phone
- +34 944818300
- Auditors
- PricewaterhouseCoopers Auditores SL
Latest News for FAE
Upcoming Events for FAE
Q1 2025 Faes Farma SA Earnings Release
Faes Farma SA Annual Shareholders Meeting
Half Year 2025 Faes Farma SA Earnings Release
Similar to FAE
Almirall SA
Madrid Stock Exchange
Grifols SA
Madrid Stock Exchange
Natac Natural Ingredients SA
Madrid Stock Exchange
Labiana Health SA
Madrid Stock Exchange
Laboratorio Reig Jofre SA
Madrid Stock Exchange
FAQ
As of Today at 20:34 UTC, shares in Faes Farma SA are trading at €4.16. This share price information is delayed by 15 minutes.
Shares in Faes Farma SA last closed at €4.16 and the price had moved by +25.15% over the past 365 days. In terms of relative price strength the Faes Farma SA share price has outperformed the FTSE Global All Cap Index by +22.02% over the past year.
The overall consensus recommendation for Faes Farma SA is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Faes Farma SA dividend yield is 4.31% based on the trailing twelve month period.
Last year, Faes Farma SA paid a total dividend of €0.18, and it currently has a trailing dividend yield of 4.31%. We do not have any data on when Faes Farma SA is to next pay dividends.
We do not have data on when Faes Farma SA is to next pay dividends. The historic dividend yield on Faes Farma SA shares is currently 4.31%.
To buy shares in Faes Farma SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €4.16, shares in Faes Farma SA had a market capitalisation of €1.29bn.
Here are the trading details for Faes Farma SA:
- Country of listing: Spain
- Exchange: MCE
- Ticker Symbol: FAE
Based on an overall assessment of its quality, value and momentum Faes Farma SA is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Faes Farma SA is €4.60. That is 10.71% above the last closing price of €4.16.
Analysts covering Faes Farma SA currently have a consensus Earnings Per Share (EPS) forecast of €0.29 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Faes Farma SA. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +14.63%.
As of the last closing price of €4.16, shares in Faes Farma SA were trading +15.85% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Faes Farma SA PE ratio based on its reported earnings over the past 12 months is 13.55. The shares last closed at €4.16.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Faes Farma SA's management team is headed by:
- Mariano Ucar Angulo - CHM
- Valentin Ruiz Unamunzaga - CFO
- Helder Cassis - GED
- Gonzalo Lopez Casanueva - GED
- Luis Proenca - GED
- Francisco Quintanilla Guerra - GED
- German Fernandez-Cano Diaz - DGD
- Francisco Perello Font - DMK
- Carlos Gutierrez Aguero - DHR
- Xavier Arnaud - OTH
- Jose Luis Diaz Capote - OTH
- Irene Diez Merchan - OTH
- Isabel Eguidazu Urruticoechea - OTH
- Alberto Fernandez Fernandez - OTH
- Ana Goicoechea Garcia - OTH
- Isidro Hermo Blanco - OTH
- Gonzalo Hernandez Herrero - OTH
- Mariana Soroa Zubiria - OTH
- Gonzalo Fernandez de Valderrama Iribarnegaray - SEC
- Carlos de Alcocer Torra - LED
- Carmen Basagoiti Pastor - DRC
- Francisco Javier Usaola Garcia - DRC
- Inigo Zavala Ortiz de la Torre - DRC
- Belen Amatriain Corbi - IND
- Maria Eugenia Zugaza Salazar - IND